tb-500 frag

the 7-amino-acid core of TB-500. half the price. half the data.

tier C · healing · frag thymosin β4 17-23

verdict

the 7-amino-acid LKKTETQ core of TB-500. half the price, half the data, all the extrapolation.

if you're asking whether the fragment matches full thymosin beta-4 — as actin-binding chemistry, yes. as a clinical equivalent to full thymosin beta-4, no convincing comparative data exists. community reports are bimodal at best and lean toward the full peptide when users have tried both at matched doses. the literature in this family (Sosne 2018, ophthalmology, the cleaner human signal in the thymosin space) is overwhelmingly on full thymosin beta-4, not the fragment.

if you're asking why the fragment exists — price. roughly 6x cheaper to synthesize than full thymosin beta-4, which translates directly to vial cost. for users priced out of full thymosin beta-4, the fragment is the obvious move. the LKKTETQ motif retains genuine in vitro actin-binding activity. whether actin binding alone reproduces the tissue-repair effects of the full peptide is exactly what the comparative evidence does not establish.

if you came in expecting TB-500 results from a fragment vial — the evidence and community track record both favor the full peptide. side-effect profiles look identical (minimal). the fragment is real biology riding on extrapolation; the full peptide already rides on extrapolation from the full thymosin beta-4 protein. that's two layers of extrapolation on what was already a community-evidence-driven compound.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because the fragment has plausible chemistry and a real mechanistic basis (actin binding) but the specific clinical claim that drives its sales, equivalence to full thymosin beta-4 at a lower price, is not supported by direct comparative evidence. Community reports are meaningfully more variable than for full thymosin beta-4. The fragment is real chemistry; the claim that it's a drop-in substitute for the A-tier parent is extrapolation. Not B-tier because that direct equivalence evidence doesn't exist. Not D-tier because the underlying pharmacology is legitimate and the fragment does have documented actin-binding activity.

the core tension

The main TB-500 entry on this site sits in A-tier and grades the market name, where third-party COAs commonly show full 43-amino-acid thymosin beta-4 in the vial, the molecule that carries the deep preclinical record and the fragile human trials. This entry is the explicitly stripped product: the 7-residue LKKTETQ sequence, residues 17-23 of thymosin beta-4, sold as a cheaper 'frag' with no chance of the full protein in it. The mechanism argument is that the actin-binding motif is where the biology happens, so the fragment should be sufficient. The counterargument is that the full protein contributes more than the motif, in stability, cellular uptake, and broader effects the fragment doesn't replicate. The clinical evidence for the bare fragment doing what full thymosin beta-4 does in real users is much thinner than the marketing implies.

what it is

tb-500 fragment is the 7-amino-acid lkktetq sequence corresponding to residues 17-23 of thymosin beta-4, the actin-binding domain of the full 43-residue parent peptide. the rest of the molecule is stripped away. cas 885340-08-9, molecular weight 858 da. classified as a research chemical, no fda approval for any indication.

what it does

the lkktetq motif retains genuine in vitro actin-binding activity. that is the characterized biochemistry. whether actin binding alone reproduces the tissue-repair and recovery effects of the full peptide, which involve cellular uptake kinetics, broader cytoskeletal interactions, and possibly receptor-mediated signaling, is exactly what the comparative evidence does not establish.

origin

emerged from research on thymosin beta-4 structure-function relationships, where lkktetq was identified as the functional core that contacts monomeric g-actin. commercial availability as a cheaper alternative to full thymosin beta-4 grew out of research-peptide supply channels rather than any clinical development program. doping-control detection studies (matabosch 2013) confirm bioavailability after administration.

why researchers are interested

price. roughly 6x cheaper to synthesize than full thymosin beta-4, which translates directly to vial cost. a meaningful minority of community users report results comparable to the full peptide. the side effect profile is identical (minimal). for users priced out of full thymosin beta-4, the fragment is the obvious move.

does it work

as actin-binding chemistry, yes. as a clinical equivalent to full thymosin beta-4, no convincing comparative data exists. community reports are bimodal at best and lean toward the full peptide when users have tried both at matched doses. the literature in this family (sosne 2018, ophthalmology) is overwhelmingly on full thymosin beta-4. the fragment is real biology riding on extrapolation. For users comparing the fragment with full thymosin beta-4, the evidence and community track record still favor the full peptide.

claims vs the data

• binds monomeric actin similarly to full thymosin beta-4 — supported — The LKKTETQ motif is the characterized actin-binding core of thymosin β4. In vitro actin-binding studies confirm the fragment retains this specific molecular function.
• produces the same tissue-repair effects as full thymosin beta-4 — weak — Mechanistic extrapolation. Full TB-500's tissue-repair effects involve more than just actin sequestration, cellular uptake, interaction with other cytoskeletal components, and potentially receptor-mediated signaling. The fragment may or may not reproduce these. Human clinical comparison data is absent.
• cheaper than full thymosin beta-4 with equivalent efficacy — partially true — The fragment is substantially cheaper to synthesize. Equivalent efficacy is the claim that lacks evidence. Community reports suggest meaningful variation in response between fragment and full peptide.
• better bioavailability due to smaller size — unverified — Smaller peptides don't automatically have better bioavailability, absorption and distribution depend on many factors including solubility, protease resistance, and tissue uptake mechanisms. No direct comparative pharmacokinetic data exists between fragment and full thymosin beta-4 in humans.
• clinical track record comparable to full thymosin beta-4 — contradicted — Full TB-500 has a much larger community user base and a longer consistency record. Fragment users are fewer, reports are more variable, and the compound hasn't accumulated the same real-world evidence base. The marketing claim of equivalence is not supported by actual community track records.

key facts

• molecular formula: C36H63N11O13
• molecular weight: 858.0 Da
• amino acids: 7
• half-life: short free-peptide plasma half-life (minutes to an hour depending on formulation); full thymosin beta-4's pharmacokinetics are better characterized than the fragment's
• type: heptapeptide fragment of thymosin β4 (actin-binding domain)
• CAS: 885340-08-9
• 7 amino acids (vs full thymosin beta-4's 43)
• actin binding primary mechanistic role of the fragment
• ~6x cheaper to synthesize than full thymosin beta-4
• minimal direct fragment-specific human trial data

frequently asked questions

What is TB-500 Frag?

TB-500 Frag refers to short peptide fragments of thymosin beta-4, most commonly the 7-amino-acid LKKTETQ sequence identified as the actin-binding motif. Sold as a cheaper research-chemical alternative to full thymosin beta-4.

What does TB-500 Frag do?

TB-500 Frag retains the actin-binding activity of the parent thymosin beta-4 protein in vitro, the chemistry is real. Whether this translates to the tissue-healing effects users expect from full thymosin beta-4 is not established; comparative community reports consistently favor the full peptide over the fragment for injury recovery outcomes.

How is TB-500 Frag typically administered?

TB-500 Frag appears in injectable research-peptide culture, usually as a cheaper alternative to full thymosin beta-4. There is no FDA-approved dosing framework or clinical program for human use of TB-500 Frag.

What are the side effects of TB-500 Frag?

Community reports are generally clean, occasional injection-site soreness is the most commonly cited effect. Because human clinical trials on the fragment specifically are absent and community use is uncontrolled, the long-term side effect profile is not characterized.

Is TB-500 Frag FDA approved?

No. TB-500 Frag has no FDA approval and is classified as a research chemical. The thymosin beta-4 peptide family falls under WADA Prohibited List S2 for competitive athletes.

How much does TB-500 Frag cost?

No clinical retail price. On the research-chemical market it is cheaper than full thymosin beta-4 due to the shorter peptide length, which is the main reason for its market position.

related peptides

• tb-500 — A-tier full thymosin β4 with genuinely strong community track record
• bpc-157 — A-tier healing partner peptide often stacked with TB-500
• bpc+tb blend — A-tier BPC-157 + TB-500 blend; its COA mass tells you which TB-500 is in it

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.